Clinical TrialsKZR-261's enrollment has stopped due to no responses seen in the study, only stable disease.
Financial PerformanceThe company ended 2Q24 with $165MM in cash, and if the current level of cash burn continues, the company may face funding challenges by 2H26.
Market DynamicsAdjusting the discount rate to 15% from 10% to reflect the increasing volume of companies entering the competitive development arena with respect to the systemic lupus erythematosus (SLE) and lupus nephritis (LN) indications.